Awaiting development: Guidance and quality standards

Skip to filters Skip to results

Showing 126 to 150 of 273

Guidance programme: Technology appraisal guidanceRemove Guidance programme: Technology appraisal guidance filter

Guidance and quality standards awaiting development
Title	Type
Ixekizumab for treating enthesitis-related arthritis and juvenile psoriatic arthritis in people 2 to 17 years [ID6590]	Technology appraisal guidance
LAM-561 with radiotherapy and temozolomide for treating IDH1 wild-type glioblastoma [ID4022]	Technology appraisal guidance
Larotrectinib for treating NTRK fusion-positive advanced solid tumours (MA review of TA630) [ID6292]	Technology appraisal guidance
Leriglitazone for treating X-linked andrenoleukodystrophy [TSID9996]	Technology appraisal guidance
Letetresgene autoleucel for treating NY-ESO-1 advanced unresectable synovial sarcoma in people aged 10 and over or NY-ESO-1 advanced unresectable myxoid round cell liposarcoma in adults [TSID10652]	Technology appraisal guidance
Liposomal cytarabine–daunorubicin for treating relapsed or refractory acute myeloid leukaemia in people aged 1 to 21 years [ID4017]	Technology appraisal guidance
Lisocabtagene maraleucel for treating relapsed or refractory low-grade B-cell follicular lymphoma after 1 or more treatments [ID6564]	Technology appraisal guidance
Luspatercept for treating anaemia in non-transfusion dependent beta-thalassaemia [ID3870]	Technology appraisal guidance
Marstacimab for treating severe haemophilia A or B in people 12 years and over with inhibitors to factor-replacement therapy [TSID12143]	Technology appraisal guidance
Mavorixafor for treating WHIM syndrome [ID3946]	Technology appraisal guidance
Mevrometostat with enzalutamide for treating hormone-relapsed metastatic prostate cancer after abiraterone acetate [TSID12239]	Technology appraisal guidance
MIM8 for preventing bleeding episodes in haemophilia A in people 1 year and over [ID6400]	Technology appraisal guidance
Mosunetuzumab with lenalidomide for treating relapsed or refractory follicular lymphoma after 1 or more systemic treatments [ID6655]	Technology appraisal guidance
Naxitamab with GM-CSF for treating relapsed or refractory high-risk neuroblastoma [ID3769]	Technology appraisal guidance
Nedosiran treating primary hyperoxaluria type 1 in people 6 years and over [TSID11777]	Technology appraisal guidance
Netarsudil for treating open angle glaucoma or ocular hypertension [ID1078]	Technology appraisal guidance
Nicardipine (Nicaplant) for aneurysmal subarachnoid haemorrhage patients undergoing aneurysm clipping [TSID10593]	Technology appraisal guidance
Niraparib with abiraterone acetate and prednisone for treating hormone-sensitive metastatic prostate cancer [ID6595]	Technology appraisal guidance
Nivolumab with ipilimumab for adjuvant treatment of localised renal cell carcinoma [TSID9659]	Technology appraisal guidance
Norucholic acid for treating primary sclerosing cholangitis [ID6583]	Technology appraisal guidance
Obinutuzumab for treating serologically active extra-renal lupus [TSID12285]	Technology appraisal guidance
Odevixibat for treating biliary atresia in children following Kasai hepatoportoenterostomy [ID6627]	Technology appraisal guidance
Odronextamab for treating relapsed or refractory follicular lymphoma [TSID12236]	Technology appraisal guidance
Omecamtiv mecarbil for treating chronic heart failure with reduced ejection fraction [ID3912]	Technology appraisal guidance
Onasemnogene abeparvovec for treating spinal muscular atrophy in people 2 years and over [TSID12168]	Technology appraisal guidance

Results per page

10
25
50
All